Reply to Intravenous Methotrexate as Central Nervous System (CNS) Prophylaxis Is Associated With a Low Risk of CNS Recurrence in High-Risk Patients With Diffuse Large B-Cell Lymphoma

被引：1
|
作者：
Abramson, Jeremy S. [1 ]
Hochberg, Ephraim P.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA 02114 USA
来源：
CANCER | 2011年 / 117卷 / 11期
关键词：
NON-HODGKIN-LYMPHOMA;
D O I：
10.1002/cncr.25788
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2580 / 2581
页数：2
相关论文
共 50 条
  • [41] Audit of central nervous system (CNS) prophylaxis in diffuse large B cell lymphoma (DLBCL) in adult patients in West of Scotland
    Nicholson, F. H.
    Sefcick, A.
    Hart, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 84 - 84
  • [42] The Efficacy of Systemic High Dose Methotrexate As Central Nervous System Prophylaxis in Patients with High Risk Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Analysis
    Lee, Kyoungmin
    Yoon, Dok Hyun
    Hong, Jung Yong
    Lee, Jung Bok
    Kim, Shin
    Park, Jung Sun
    Huh, Jooryung
    Lee, Sang Wook
    Suh, Cheolwon
    BLOOD, 2017, 130
  • [43] Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era
    Zhang, Nianhai
    Xu, Deming
    Liu, Bo
    Shi, Xi
    Xie, Xianhe
    Wang, Zili
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
  • [44] Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma
    Ollila, Thomas A.
    Kurt, Habibe
    Waroich, Jozal
    Vatkevich, John
    Sturtevant, Ashlee
    Patel, Nimesh R.
    Dubielecka, Patrycja M.
    Treaba, Diana O.
    Olszewski, Adam J.
    BLOOD, 2021, 137 (08) : 1120 - 1124
  • [45] Risk Factors for Central Nervous System (CNS) Relapse after Autologous Stem Cell Transplant (ASCT) in Diffuse Large B-Cell Lymphoma (DLBCL)
    Terasaki, Yukie
    Shimizu, Hiroaki
    Miyazawa, Yuri
    Toyama, Kohtaro
    Koiso, Hiromi
    Yokohama, Akihiko
    Matsumoto, Morio
    Ogura, Hidemi
    Naito, Chiaki
    Tsukamoto, Norifumi
    Handa, Hiroshi
    BLOOD, 2019, 134
  • [46] Lack of Influence of Rituximab and CNS Directed Prophylactic Therapy on CNS Relapse in High-Risk Diffuse Large B Cell Lymphoma
    Yellu, Mahender
    Malek, Ehsan
    Thavalathil, Berry
    Latif, Tahir
    BLOOD, 2014, 124 (21)
  • [47] CNS prophylaxis in diffuse large B-cell lymphoma: If, when, how and for whom?
    Siegal, Tali
    Goldschmidt, Neta
    BLOOD REVIEWS, 2012, 26 (03) : 97 - 106
  • [48] Patient selection and tolerability of high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma
    Melissa J. Garwood
    Eliza A. Hawkes
    Leonid Churilov
    Geoffrey Chong
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 133 - 140
  • [49] The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma
    Wei, Xiaolei
    Guo, Xutao
    Wei, Qi
    Xiong, Dan
    Zhang, Peng
    Zhang, Zewen
    Wei, Yongqiang
    Feng, Ru
    BLOOD, 2024, 144 : 1740 - 1740
  • [50] Association of circulating tumor DNA from the cerebrospinal fluid with high-risk CNS involvement in patients with diffuse large B-cell lymphoma
    Wang, Xiaoxiao
    Gao, Yan
    Shan, Changguo
    Lai, Mingyao
    He, Haixia
    Bai, Bing
    Ping, Liqin
    Rong, Qixiang
    Ai, Ruyu
    Wen, Lei
    Zhou, Zhaoming
    Yu, Ruoying
    Ou, Qiuxiang
    Wu, Xue
    Wang, Xiaoxia
    Shao, Yang W.
    Cai, Linbo
    Huang, Huiqiang
    CLINICAL AND TRANSLATIONAL MEDICINE, 2021, 11 (01):
12345